Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure.

To determine whether disruption of vascular endothelial growth factor (VEGF)-VEGF receptor (VEGFR) signaling in the newborn has long-term effects on lung structure and function, we injected 1-day-old newborn rat pups with a single dose of Su-5416, a VEGFR inhibitor, or vehicle (controls). Lungs from infant (3-wk-old) and adult (3- to 4-mo-old) rats treated with Su-5416 as newborns showed reductions in arterial density (82 and 31%, respectively) and alveolar counts (45 and 29%) compared with controls. Neonatal treatment with Su-5416 increased right ventricle weight to body wt ratios (4.2-fold and 2.0-fold) and pulmonary arterial wall thickness measurements (2.7-fold and 1.6-fold) in infant and adult rats, respectively, indicating marked pulmonary hypertension. We conclude that treatment of newborn rats with the VEGFR inhibitor Su-5416 impaired pulmonary vascular growth and postnatal alveolarization and caused pulmonary hypertension and that these effects were long term, persisting well into adulthood.

[1]  P. Heikkilä,et al.  Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. , 2001, American journal of respiratory and critical care medicine.

[2]  R. Watkins,et al.  Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. , 2001, American journal of respiratory and critical care medicine.

[3]  D. Stewart,et al.  Cell-Based Gene Transfer of Vascular Endothelial Growth Factor Attenuates Monocrotaline-Induced Pulmonary Hypertension , 2001, Circulation.

[4]  K. Goss,et al.  VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[5]  I. Zachary.  Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. , 2001, American journal of physiology. Cell physiology.

[6]  N. Ferrara.  Role of vascular endothelial growth factor in regulation of physiological angiogenesis. , 2001, American journal of physiology. Cell physiology.

[7]  J. Cherrington,et al.  The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. , 2001, Blood.

[8]  N. Ferrara,et al.  Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) , 2001, The Journal of Biological Chemistry.

[9]  P. Hirth,et al.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  P. Hirth,et al.  Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. , 2000, The Journal of clinical investigation.

[11]  J. Cherrington,et al.  The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  S. Eddahibi,et al.  Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. , 2000, American journal of respiratory cell and molecular biology.

[13]  D. Barker.  Fetal Origins of Cardiovascular and Lung Disease , 2000 .

[14]  N. Voelkel,et al.  Inhibition of angiogenesis decreases alveolarization in the developing rat lung. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[15]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[16]  T. L. Le Cras,et al.  Neonatal dexamethasone treatment increases the risk for pulmonary hypertension in adult rats. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[17]  A. Jobe.  The New BPD: An Arrest of Lung Development , 1999, Pediatric Research.

[18]  V Hombach,et al.  A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. , 1999, Circulation research.

[19]  M. Haase,et al.  Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flk1 and Flt1 in bleomycin-induced rat lung fibrosis , 1999, Virchows Archiv.

[20]  A. Ristimäki,et al.  Vascular endothelial growth factor in human preterm lung. , 1999, American journal of respiratory and critical care medicine.

[21]  M Aguet,et al.  VEGF is required for growth and survival in neonatal mice. , 1999, Development.

[22]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[23]  J. Sterne,et al.  Birth weight, childhood lower respiratory tract infection, and adult lung function , 1998, Thorax.

[24]  D. Sawyer,et al.  Early fetal development of lung vasculature. , 1997, American journal of respiratory cell and molecular biology.

[25]  C. D’Angio,et al.  Hyperoxic injury decreases alveolar epithelial cell expression of vascular endothelial growth factor (VEGF) in neonatal rabbit lung. , 1997, American journal of respiratory cell and molecular biology.

[26]  J. Stocks,et al.  Lung development and early origins of childhood respiratory illness. , 1997, British medical bulletin.

[27]  E. Baraldi,et al.  Pulmonary function until two years of life in infants with bronchopulmonary dysplasia. , 1997, American journal of respiratory and critical care medicine.

[28]  W. Hop,et al.  Long-term pulmonary sequelae in children with congenital diaphragmatic hernia. , 1997, American journal of respiratory and critical care medicine.

[29]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[30]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[31]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[32]  L. N. Blanco,et al.  Alveolar dimensions and number: developmental and hormonal regulation. , 1989, The American journal of physiology.

[33]  W M Thurlbeck,et al.  The radial alveolar count method of Emery and Mithal: a reappraisal 1--postnatal lung growth. , 1982, Thorax.

[34]  W. Thurlbeck,et al.  The radial alveolar count method of Emery and Mithal: a reappraisal 2--intrauterine and early postnatal lung growth. , 1982, Thorax.

[35]  L. Reid,et al.  Pulmonary arterial and alveolar development in normal postnatal rat lung. , 1982, The American review of respiratory disease.

[36]  A. Nadas,et al.  Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. , 1979, The American journal of physiology.

[37]  L. Reid,et al.  New findings in pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. , 1976, British journal of experimental pathology.

[38]  J. Emery,et al.  The Number of Alveoli in the Terminal Respiratory Unit of Man During Late Intrauterine Life and Childhood , 1960, Archives of disease in childhood.